Acne Vulgaris Therapeutics Market Research 2024: Comprehensive Insights About 20+ Companies and 22+ Pipeline Drugs - Revolutionary Advances Poised to Change the Future Treatment [Yahoo! Fi...
Dermata Therapeutics, Inc. (DRMA)
Company Research
Source: Yahoo! Finance
The landscape of Acne Vulgaris treatment is on the brink of transformation with over 20 pharmaceutical companies and academic institutions proactively developing more than 22 innovative pipeline drugs. These endeavors aim to address the multifaceted nature of Acne Vulgaris, which affects individuals globally with implications beyond physical scarring – extending into emotional and psychological distress. The treatment pipeline targets various stages and forms of the disease with a focus on novel mechanisms of action and delivery methods. Cutting-edge Therapeutic Approaches and Clinical Progress Highlighted in the insights are promising therapies that herald a new era in Acne Vulgaris care. Berdazimer sodium (SB 204) by Pelthos Therapeutics, at the forefront in phase III trials, exhibits potential as a first-in-class nitric oxide-releasing topical treatment with a favorable safety profile. Another promising candidate is DMT310 by Dermata Therapeutics, derived from a natural Spongi
Show less
Read more
Impact Snapshot
Event Time:
DRMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DRMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DRMA alerts
High impacting Dermata Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DRMA
News
- Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsAccesswire
- Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024GlobeNewswire
- Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024Accesswire
- Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
- Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq RulesAccesswire
DRMA
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form 8-K
- 11/13/24 - Form 10-Q
- DRMA's page on the SEC website